Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma

Clinical trial NCT05389527 · UNKNOWN

Trial details

NCT number: NCT05389527
Sponsor: Shanghai Zhongshan Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Hepatocellular

Start date: 2022-09-30
Primary completion: 2023-12-15
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.